Drugs / Wosulin R
Wosulin R
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00772265 | Sep 2010 → Mar 2011 | diabetes mellitus | Wockhardt | Completed | No outcome recorded |
| Phase 1 | NCT00752180 | Aug 2008 → Mar 2009 | diabetes mellitus | Wockhardt | Completed | No outcome recorded |
| Phase 1 | NCT00719108 | Jul → Sep 2008 | diabetes mellitus | Wockhardt | Completed | No outcome recorded |
| Phase 1 | NCT00596063 | Jan → Feb 2008 | diabetes mellitus | Wockhardt | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Wosulin R | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00719108 ↗ |
| Known as | Isophane insulin | “Wosulin N, Isophane insulin for injection (Recombinant Human Insulin)(100 IU/mL), cartridges 3.0 mL” NCT00772265 ↗ |
| Known as | Recombinant Human Insulin | “Wosulin N, Isophane insulin for injection (Recombinant Human Insulin)(100 IU/mL), cartridges 3.0 mL” NCT00772265 ↗1“Wosulin R, Regular insulin for injection (Recombinant Human Insulin) (100 IU/mL)in vials 10.0 ml” NCT00719108 ↗ |
| Known as | Wosulin N | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00772265 ↗ |
| Modality | Protein / enzyme biologic | “recombinant human insulin” NCT00596063 ↗ |
| Route | Subcutaneous | “administered subcutaneously” NCT00596063 ↗ |